Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KRP203 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KRP203 - 1.2 mg | EXPERIMENTAL | - |
| Placebo to KRP203 - 1.2 mg | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KRP203 - 1.2mg | DRUG | - |
| Placebo to KRP203 - 1.2 mg | DRUG | - |
Inclusion Criteria: * Male and female patients,18 to 65 years of age inclusive, who have been defined as having SCLE based on the typical clinical picture and the characteristic histopathological features as described by Sontheimer et al. at least three months before study entry (screening) Exclus...
KRP203 is an investigational small molecule being studied for the treatment of subacute cutaneous lupus erythematosus, an autoimmune skin condition. It has been evaluated in a Phase 2 clinical trial in adults with this indication. KRP203 is not approved for any use and remains in clinical development.
KRP203 is being developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 2 clinical trial of KRP203 in subacute cutaneous lupus erythematosus. No other developers or partners for KRP203 have been disclosed.
KRP203 is in Phase 2 development. It has completed one Phase 2 clinical trial in subacute cutaneous lupus erythematosus. There are currently no active trials of KRP203. The drug is investigational and has not been approved by the FDA or any other regulatory agency.
KRP203 has been studied in one completed Phase 2 trial, NCT01294774, titled Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus. The trial enrolled 10 adults, was randomized, double-blind, and placebo-controlled, and was conducted in Germany, Greece, and Italy.